probucol has been researched along with Acute Kidney Failure in 9 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol with hydration decreases the CI-AKI incidence compared to hydration only in patients with coronary heart disease undergoing CAG or PCI." | 9.41 | Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials. ( Cui, X; Liu, F; Mei, L; Qin, F; Wang, H; Xie, B; Yi, X; Zhang, J, 2023) |
| "This study was performed to explore the effects of probucol on contrast-induced acute kidney injury (CIAKI) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 9.30 | Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. ( Ge, W; Lu, C; Shi, Y; Wang, Y; Xu, X; Yang, S, 2019) |
| "Probucol, a lipid-lowering drug with potent antioxidant properties, may reduce the risk of cystatin C (CyC)-based contrast-induced acute kidney injury (CIAKI)." | 9.17 | Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial. ( Che, J; Chen, X; Fan, Z; He, M; Li, F; Li, G; Li, Y; Liu, E; Liu, T; Liu, X; Ma, X; Ruan, Y; Wu, L; Xu, G; Xu, Y; Yin, L; Yuan, R; Zheng, X, 2013) |
| "The results of pilot randomized controlled trials (RCTs) evaluating probucol treatment on the risk of contrast-induced acute kidney injury (CI-AKI) are inconsistent." | 9.01 | Probucol for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary intervention: A meta-analysis of randomized controlled trials . ( Jia, S; Lin, Z; Xin, W; Zhang, T, 2019) |
| "Probucol was administered by gavage and the contrast diatrizoate (60%) was injected via femoral vein." | 5.51 | Probucol Protects Against Contrast-Induced Acute Kidney Injury via the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2)/JNK-Caspase 3 Pathway in Diabetic Rats. ( Chen, J; Jiao, Z; Li, G; Liu, T; Liu, Y; Ma, X; Tse, G; Yuan, R, 2019) |
| "Probucol with hydration decreases the CI-AKI incidence compared to hydration only in patients with coronary heart disease undergoing CAG or PCI." | 5.41 | Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials. ( Cui, X; Liu, F; Mei, L; Qin, F; Wang, H; Xie, B; Yi, X; Zhang, J, 2023) |
| "This study was performed to explore the effects of probucol on contrast-induced acute kidney injury (CIAKI) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI)." | 5.30 | Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. ( Ge, W; Lu, C; Shi, Y; Wang, Y; Xu, X; Yang, S, 2019) |
| "Probucol, a lipid-lowering drug with potent antioxidant properties, may reduce the risk of cystatin C (CyC)-based contrast-induced acute kidney injury (CIAKI)." | 5.17 | Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial. ( Che, J; Chen, X; Fan, Z; He, M; Li, F; Li, G; Li, Y; Liu, E; Liu, T; Liu, X; Ma, X; Ruan, Y; Wu, L; Xu, G; Xu, Y; Yin, L; Yuan, R; Zheng, X, 2013) |
| "The results of pilot randomized controlled trials (RCTs) evaluating probucol treatment on the risk of contrast-induced acute kidney injury (CI-AKI) are inconsistent." | 5.01 | Probucol for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary intervention: A meta-analysis of randomized controlled trials . ( Jia, S; Lin, Z; Xin, W; Zhang, T, 2019) |
| "Uric acid has ever been considered as one of contrast induced acute kidney injury's risk factors." | 3.80 | Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure. ( Cong, H; Fu, N; Jin, D; Li, H; Li, X; Ma, H; Wang, Y, 2014) |
| "The effects of antioxidant therapy with probucol were evaluated in rats subjected to 1 h renal ischemia and to 24 h reperfusion." | 3.67 | Ischemic acute renal failure and antioxidant therapy in the rat. The relation between glomerular and tubular dysfunction. ( Bird, JE; Blantz, RC; Milhoan, K; Mundy, CA; Parthasarathy, S; Wilson, CB; Young, SG, 1988) |
| "Probucol was administered by gavage and the contrast diatrizoate (60%) was injected via femoral vein." | 1.51 | Probucol Protects Against Contrast-Induced Acute Kidney Injury via the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2)/JNK-Caspase 3 Pathway in Diabetic Rats. ( Chen, J; Jiao, Z; Li, G; Liu, T; Liu, Y; Ma, X; Tse, G; Yuan, R, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, X | 1 |
| Xie, B | 1 |
| Wang, H | 1 |
| Liu, F | 1 |
| Mei, L | 1 |
| Qin, F | 1 |
| Zhang, J | 1 |
| Yi, X | 1 |
| Ma, X | 2 |
| Jiao, Z | 1 |
| Liu, Y | 1 |
| Chen, J | 1 |
| Li, G | 3 |
| Liu, T | 4 |
| Tse, G | 1 |
| Yuan, R | 3 |
| Xin, W | 1 |
| Lin, Z | 1 |
| Zhang, T | 1 |
| Jia, S | 1 |
| Wang, Y | 2 |
| Shi, Y | 1 |
| Xu, X | 1 |
| Ge, W | 1 |
| Yang, S | 1 |
| Lu, C | 1 |
| Li, H | 1 |
| Li, X | 1 |
| Ma, H | 1 |
| Fu, N | 1 |
| Jin, D | 1 |
| Cong, H | 1 |
| Yin, L | 3 |
| Zheng, X | 2 |
| Xu, G | 2 |
| Xu, Y | 2 |
| Che, J | 2 |
| Liu, H | 1 |
| Zhou, L | 1 |
| Chen, X | 3 |
| He, M | 3 |
| Li, Y | 2 |
| Wu, L | 2 |
| Liu, E | 2 |
| Li, GP | 1 |
| Liu, HM | 1 |
| Zheng, XT | 1 |
| Liu, EZ | 1 |
| Zhou, LJ | 1 |
| Liu, X | 1 |
| Li, F | 1 |
| Fan, Z | 1 |
| Ruan, Y | 1 |
| Bird, JE | 1 |
| Milhoan, K | 1 |
| Wilson, CB | 1 |
| Young, SG | 1 |
| Mundy, CA | 1 |
| Parthasarathy, S | 1 |
| Blantz, RC | 1 |
2 reviews available for probucol and Acute Kidney Failure
| Article | Year |
|---|---|
Preventing contrast-induced acute kidney injury with probucol and hydration in patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Kidney Injury; Contrast Media; Coronary Angiography; Coronary Disease; Drug-Related Side Effec | 2023 |
Probucol for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary intervention: A meta-analysis of randomized controlled trials
.
Topics: Acute Kidney Injury; Antioxidants; Contrast Media; Coronary Angiography; Creatinine; Fluid Therapy; | 2019 |
4 trials available for probucol and Acute Kidney Failure
| Article | Year |
|---|---|
Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention.
Topics: Acute Kidney Injury; Aged; Antioxidants; China; Contrast Media; Coronary Angiography; Coronary Disea | 2019 |
Role of probucol in preventing contrast-induced acute kidney injury after coronary interventional procedure.
Topics: Acute Kidney Injury; Aged; Angioplasty, Balloon, Coronary; Antioxidants; Contrast Media; Coronary An | 2009 |
[Role of probucol in preventing contrast induced acute kidney injury after coronary interventional procedure: a randomized trial].
Topics: Acute Kidney Injury; Aged; Angina, Unstable; Contrast Media; Coronary Angiography; Female; Humans; M | 2009 |
Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial.
Topics: Acute Kidney Injury; Aged; Ambulatory Care; Angioplasty, Balloon, Coronary; Biomarkers; Contrast Med | 2013 |
3 other studies available for probucol and Acute Kidney Failure
| Article | Year |
|---|---|
Probucol Protects Against Contrast-Induced Acute Kidney Injury via the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2)/JNK-Caspase 3 Pathway in Diabetic Rats.
Topics: Acute Kidney Injury; Animals; Antioxidants; Apoptosis; Caspase 3; Contrast Media; Diabetes Mellitus, | 2019 |
Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure.
Topics: Acute Kidney Injury; Aged; Antioxidants; Atorvastatin; Biomarkers; Contrast Media; Drug Therapy, Com | 2014 |
Ischemic acute renal failure and antioxidant therapy in the rat. The relation between glomerular and tubular dysfunction.
Topics: Acute Kidney Injury; Animals; Chemical Phenomena; Chemistry; Glomerular Filtration Rate; Inulin; Isc | 1988 |